184 results about "Tumor progression" patented technology

The invention provides an intelligent tumor nursing monitoring system. The intelligent tumor nursing monitoring system comprises a data acquisition module, a data processing module, a dynamic evaluation module, a multi-stage early warning module and a self-adaptive control module. The data acquisition module acquires physiological sign data, tumor local image data and body fluid biochemical data of a patient in real time through a multi-source biosensor. And the data processing module performs space-time alignment, noise suppression and cross-modal feature association on the multi-modal data to generate a comprehensive feature map. The dynamic evaluation module calculates the tumor progress rate and the complication risk coefficient based on the map, and generates a personalized risk prediction curve. And the multi-stage early warning module triggers an early warning signal according to the curve and generates a risk traceability report. And the adaptive control module generates a personalized scheme based on the early warning signal and the traceability report and controls the medical equipment to execute closed-loop feedback adjustment. The nursing quality and the treatment effect of tumor patients can be improved, and the medical risk is reduced.

The invention relates to an application of alvitinib in preparation of an NLRP3 inflammasome inhibitor. The alvetinib is used for preparing a medicament for treating infectious shock, a medicament for treating acute liver injury and a medicament for treating peritonitis. A new choice is provided for prevention or treatment of NLRP3 inflammasome related diseases, the problem of treatment of EGFR mutation lung cancer patients combined with NLRP3 inflammasome related diseases (infectious shock / acute liver injury / acute peritonitis) is solved, tumor progression and inflammatory response are inhibited at the same time through the Aviitinib (third-generation EGFR-TKI), and the NLRP3 inflammasome related diseases are treated through the Aviitinib (third-generation EGFR-TKI). It is suggested that the medicine is preferentially selected by the patients, and the medicine with higher treatment potential is provided for treatment of infectious shock medicines, acute liver injury medicines and acute peritonitis.

The present invention relates to combined therapy of cancer using an epithelial cell adhesion molecule (EpCAM) inhibitor and a Wnt signaling inhibitor. Specifically, the EpCAM inhibitor is an antibody which is directed to an extracellular domain (EpEX) of EpCAM. The combined therapy is effective in inducing apoptosis of cancer cells, inhibiting cancer sternness properties, tumor progression and / or metastasis, and / or prolonging survival of a cancer patient.

A computer implemented method of distinguishing tumor progression from treatment-related necrosis in digital images of a subject implements a multimodal deep learning architecture from MRI data of a selected anatomical portion of the subject, such as a brain, and corresponding dPET data for the subject with a tracer applied to the anatomical portion of the subject. The computer stores co-registered MRI data frames with dPET data frames as three dimensional (3D) parametric PET maps to identify multi-modal image features of segmented tumor data. A convolutional neural network uses MRI data and selected multi-modal image features as inputs and the computer concatenates respective output latent feature vectors from the respective sections of the at least one CNN. Feeding concatenated feature vectors to fully connected layers of the multimodal architecture distinguishes tumor progression from treatment-related necrosis of the anatomical portion of the subject.

The invention provides application of an ENO1K71R mutant as a target spot in screening preparations for regulating and controlling glycolysis of colon cancer cells and improving tumor microenvironment, and belongs to the technical field of biological medicine and molecular biology. The research on the colon cancer cells which stably knock down PCSK9 finds that PCSK9 achieves the regulation effect on lactic acid metabolism in the colon cancer cells by regulating ENO1 lactic acid modification, the blank of ENO1 protein lactic acid modification and the regulation effect of the ENO1 protein lactic acid modification in tumor progression is filled, a lactic acid modification site is verified by constructing an ENO1K71R mutation experience, and the result shows that the PCSK9 can be used for regulating the lactic acid metabolism in the colon cancer cells. After ENO1 (K71) point mutation, ENO1 lactic acid can be inhibited, a new site is provided for ENO1 lactic acid modification, and a theoretical basis is also provided for developing novel tumor targeted drugs.

The invention belongs to the technical field of gene engineering, and relates to an esophageal squamous cell carcinoma diagnostic kit based on a peripheral blood mononuclear cell methylation marker and application. The kit comprises a primer pair which is used for detecting the methylation of a cg05914150 site, a cg06769875 site, a cg07475126 site, a cg08433285 site, a cg10038907 site, a cg17968322 site, a cg19572487 site, a cg20184330 site, a cg22741248 site and a cg22823192 site. According to the detection kit provided by the invention, the type of a detected sample is peripheral blood, the sample is relatively easy to obtain and non-invasive, and the patient compliance is relatively good. Abnormal methylation changes mostly exist in the early progression process of tumors, early diagnosis of ESCC can be achieved through the methylation detection method provided by the invention, and the five-year survival rate of ESCC patients is effectively increased.

The invention discloses an immunoregulatory factor composition, which comprises a first component and a second component, the first component is a type I cytokine or a long-acting form thereof, and the second component is a type II cytokine or a long-acting form thereof; the long-acting form is formed by fusing a cell factor with a fusion partner through a connecting peptide or performing PEGylation modification on the cell factor, and the fusion partner is an Fc fragment of IgG or human serum albumin or an engineered mutant of one of the Fc fragment and the human serum albumin. The immunomodulatory factor composition synergistically activates precursor depleted CD8 + T cells and terminal depleted CD8 + T cells through a combination therapy of type I and type II cytokines. The invention also discloses nucleic acid, a carrier and a cell related to the immunomodulatory factor composition. The invention also discloses an application of the immunoregulatory factor composition in preparation of drugs for treating cancers. The immunoregulatory factor composition can relieve the depletion state of depleted T cells and improve the effector function and proliferation capacity of the depleted T cells so as to control tumor progression.

The invention provides a compound for releasing a urine fluorescent biomarker under induction of mitochondrial DNA mutation as well as a preparation method and application of the compound, and belongs to the technical field of medicines. The compound disclosed by the invention is prepared by the following steps: complementarily pairing a hybrid nucleic acid nano-carrier containing single-stranded DNA (Deoxyribose Nucleic Acid), an annular fluorescent reporter molecule and a Cas12a / crRNA compound through bases of DNA or RNA, and then coating polyethyleneimine and hyaluronic acid. A CRISPR / Cas12a system is selected as a converter of tumor specific mitochondrial DNA mutation information and urine fluorescence signals, a nano delivery system which responds to mtDNA single base mutation and is used for tumor progress monitoring and early metastasis warning is designed and synthesized, and the nano delivery system has a good application prospect in tumor progress monitoring and early metastasis sensitive detection.

The invention relates to the technical field of biomedicine. The invention provides a phosphorylated protein marker for angiogenesis of glioma and application of the phosphorylated protein marker. Through a series of analysis such as iTRAQ quantitative phosphorylated proteomics, KEGG signal channel enrichment, a kinase spectrum, glioblastoma transcriptome high-throughput sequencing data and immunohistochemistry, it is determined that significantly different phosphorylated proteins and related signal channels can significantly affect neuroglioma angiogenesis; and the phosphorylated protein changes along with tumor progression, and is a phosphorylated protein marker and a potential therapeutic target for glioma angiogenesis.

The present invention belongs to the field of biological technology, and specifically relates to a method for predicting the risk of tumor re-progression after hepatic artery embolization chemotherapy. The method comprises determining core characteristic variables in collected data, and using a 0-8 week data set, an 8-12 week data set, a 12-16 week data set, and a >16 week data set as training sets, performing data enhancement processing, and respectively training neural networks to obtain a first cycle prediction network, a second cycle prediction network, a third cycle prediction network, and a fourth cycle prediction network; inputting the data to be tested into four prediction networks respectively to obtain corresponding probabilities, selecting the maximum value among the four probability values ​​as a prediction result, and the corresponding time period as a prediction period of tumor re-progression; thereby realizing individualized risk prediction of tumor re-progression, so as to facilitate the formulation of an individualized plan.

The invention relates to the technical field of biological medicine, and provides a Chinese herbal medicine vesicle-LNP hybrid tumor mRNA vaccine and application thereof. The tumor mRNA vaccine disclosed by the invention is obtained by hybridizing Chinese herbal medicine nano-vesicles and lipid nano-particles loaded with tumor antigen mRNA. According to the invention, the characteristic of good biocompatibility of Chinese herbal medicines is utilized, so that the safety risk of the cationic lipid carrier is reduced. By combining the characteristics of Chinese herbal medicines, the nano-vesicles are extracted, so that the LNP is promoted to more effectively target antigen-presenting cells, the uptake level of the antigen-presenting cells is promoted, the phagocytosis of mRNA is enhanced, and the targeting and transcriptional expression level of mRNA can be enhanced. Finally, the Chinese herbal medicine nano vesicle-LNP hybrid tumor mRNA vaccine can strengthen the curative effects of inhibiting tumor progression, tumor recurrence and tumor metastasis after the tumor mRNA vaccine is inoculated, and a path is opened up for the combination of the tumor mRNA vaccine and richer immunotherapy means.

The invention relates to an SR-B1 targeted polypeptide compound and application thereof in preparation of antitumor drugs and immunotherapy sensitizers, and belongs to the technical field of biological drug manufacturing. In order to solve the problems that an existing PD-L1 inhibitor is single in action mechanism and immune system dysfunction is easily caused, the invention provides an SR-B1 targeted polypeptide compound which is composed of SR-B1 targeted polypeptide and Resiquimod. The SR-B1 targeting polypeptide comprises an SR-B1 targeting peptide fragment, a self-assembly peptide fragment and a hydrophobic molecule which are connected in sequence. The SR-B1 targeting polypeptide can recognize overexpressed SR-B1 in tumor cells, block cholesterol uptake, inhibit tumor progression and inhibit expression of PD-L1 at the same time. The polypeptide compound accurately delivers Resiquimod to a tumor site, anti-tumor immune response is activated, and sensitivity of tumor immunotherapy is greatly enhanced through combination of cholesterol metabolism regulation and immunotherapy.

The invention discloses siRNA (small interfering Ribonucleic Acid) targeting TMEM86A and application thereof, and relates to the technical field of biology, the siRNA comprises the following positive-sense strands and antisense strands: siRNA-001: a positive-sense strand: 5 '-GAAGAGCGAAGGACCCAAATT-3'; according to the tumor-associated macrophage, TMEM86A has a positive-sense strand of 5 '-TTTGGGTCCTTCGCTTCT-3', an antisense strand of 5 '-TTTGGGTCCTGTCGCTTCT-3', siRNA-002 has a positive-sense strand of 5 '-GGCTCATGGTTCGGTTTT-3', and an antisense strand of 5 '-AAACCGAACCCATGAGCCT-3'. According to the tumor-associated macrophage, single cell sequencing analysis finds that TMEM86A is highly expressed in tumor-associated macrophages, and the development of tumors is inhibited by designing siRNA of TMEM86A to target the tumor-associated macrophages in a colon cancer tumor microenvironment.

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

This invention discloses the application of integrin αv inhibitors combined with γ-secretase inhibitors in the preparation of drugs for treating tumors. The study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors in tumor treatment exhibits a synergistic effect, not only inhibiting in situ tumor growth but also significantly suppressing tumor invasion, distant metastasis, and other malignant progression, thus helping to slow tumor progression, improve treatment efficacy, and enhance patient prognosis. Furthermore, the study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors can reduce the production of the intracellular free domain of integrin αv and inhibit the activation of the classical downstream pathway of integrin αv. The combined use of integrin αv inhibitors and γ-secretase inhibitors shows broad application prospects in tumor treatment.

The technical problem to be solved by the invention is to provide the ovarian cancer tumor immune microenvironment in-vitro model based on the micro-fluidic chip and the use method. The in-vitro model is beneficial to systematic understanding of individual effects and synergistic effects of all components in tumor progression, and can also guide use of related drugs and predict drug use effects. The in-vitro model comprises a chip body, at least one culture medium flow channel is formed in the left end face of the chip body, at least one group of organ-like holes are formed in the upper surface of the chip body in the left-right direction of the chip body and communicated with the culture medium flow channel under the organ-like holes, a Transwell chamber is embedded in each organ-like hole, and the in-vitro model further comprises a culture medium injection device; compared with a traditional co-culture model, the chip model is closer to an in-vivo real condition and has time priority in the aspect of immune response change; in-vitro study on the unique tumor immune microenvironment of the ovarian cancer is facilitated, and meanwhile, the change condition of the tumor immune microenvironment after in-vivo drugs are used is also facilitated.

The present invention provides combination therapies for reducing or preventing tumor progression or treating cancer using a binding agent comprising at least one binding region that binds CD27 in combination with a PD1 / PD-L1 inhibitor.

This invention belongs to the field of biopharmaceutical technology and specifically relates to the use of NT5M in the preparation of a drug for the treatment of pancreatic cancer. The invention reveals that NT5M is a key metabolic regulator in PAAD, influencing tumor progression, immune regulation, and drug sensitivity. Low NT5M expression is associated with poor prognosis, while its overexpression inhibits cell migration, invasion, and PD-L1-mediated immune evasion, highlighting its potential as a tumor suppressor in PAAD. It can serve as both a prognostic biomarker and a potential therapeutic target, providing a new treatment strategy for PAAD patients.

The invention belongs to the technical field of biological medicine, and particularly relates to application of GLUT5 serving as a colorectal cancer biomarker in development of an in-vitro detection kit, a prognosis model and an inhibitor. The GLUT5 is highly expressed in colorectal cancer tumor-related fibroblasts (CAFs), the expression level of the GLUT5 is remarkably related to poor prognosis of a patient, and the GLUT5 can be used as a molecular basis for auxiliary diagnosis and an independent prognosis factor. In mechanism, the GLUT5 promotes tumor progression by mediating fructose metabolism reprogramming of the CAFs. A full-chain solution from early diagnosis and precise prognosis to targeted therapy is provided for colorectal cancer, and the clinical transformation value is remarkable.

Described herein are particle-driven radiogenomics systems and methods that can be used to identify imaging features for prediction of intratumoral and interstitial nanoparticle distributions in cancers (e.g., in low grade and / or high-grade brain cancers (e.g., gliomas, e.g., primary gliomas)). In certain embodiments, the systems and methods described herein extract and combine quantitative multi-dimensional data generated from structural, functional, and / or metabolic imaging. In certain embodiments, the combined multidimensional data is linked to intratumoral and interstitial nanoparticle distributions. For example, this linked data can be used to determine quantitative functional-metabolic multimodality particle-based imaging features and to predict treatment efficacy. These techniques provide an improved quantitative ability to measure treatment response and determine tumor progressions compared to traditional size-based imaging methods.

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.

The invention relates to application of a KRT7-AS inhibitor in preparation of a medicine for treating ovarian cancer or paclitaxel drug resistance of the ovarian cancer. The invention discloses a mechanism of KRT7-AS for promoting ovarian cancer progression by inhibiting ferroptosis for the first time. After KRT7-AS is knocked down by utilizing an shRNA (short hairpin ribonucleic acid) inhibition technology, biological behaviors of ovarian cancer cells and ovarian cancer paclitaxel drug-resistant cells are influenced: proliferation, migration and invasion capabilities are reduced to different degrees, and meanwhile, ferroptosis is activated to inhibit tumor growth. The invention provides a new thought and a potential target for precise treatment of ovarian cancer, and is expected to bring good news to ovarian cancer patients. Long-chain non-coding RNA KRT7-AS is novel carcinogenic lncRNA of ovarian cancer, and the effect of KRT7-AS knockout in the ovarian cancer cell process is researched. By targeting KRT7-AS, ferroptosis of ovarian cancer cells is regulated and controlled, so that tumor progression is influenced. The KRT7-AS inhibitor is used for targeting KRT7-AS, can be used as a treatment method for treating ovarian cancer, and is an innovative strategy for treating ovarian cancer.

The invention provides a pilot small-molecule compound and application thereof, the structural formula of the pilot small-molecule compound is shown in the specification, and application of the small-molecule compound in preparation of a preparation for inhibiting FGL2 activity. The pilot small molecule compound provided by the invention can be combined with FGL2 protein to play a role in inhibiting the FGL2 protein, so that the development process of tumors is slowed down.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

Exemplary system and methods propagate a lesion to measure tumor progression and response. Plural images of a patient obtained during plural computed tomography scans are received which include a set of baseline images and a set of supplement images obtained at a different time points. Each received image is analyzed to detect an organ and perform organ segmentation on the image in which an organ is detected. A contour for at least one baseline image in the set of baseline images on which organ segmentation is performed is received from a user. The annotated baseline image is aligned onto a supplement image of the set of supplement images. The aligned images are registered based on the lesion of interest, and universal lesion segmentation is performed to predict new lesion contours. Biomarkers are extracted from the registered and aligned images based on new lesion contours associated with the lesion of interest.

Aspects of the disclosure provide a formulation for treating advanced pancreatic cancer, comprising a combination of a cannabinoid, a terpene, and a flavonoid. To enhance bioavailability and targeted delivery, the formulation is incorporated into a nanoplatform, such as a nanoemulsion, optimizing absorption and delivery to cancer cells. The nanoparticle-based composition specifically targets advanced stages of pancreatic cancer, aiming to inhibit tumor progression and improve clinical outcomes.

Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same.

The disclosure relates generally to methods for treating or slowing progression of a tumor, a neurodegenerative disease or a cognitive impairment, and for improving cognition, comprising administration of light therapy. The disclosure also relates to methods for activating oral stem cells, comprising administration of light therapy. Further provided herein are methods for improving cognition, comprising administering to the oral cavity of a subject in need thereof an effective amount of light. Additionally provided herein are methods for treating autism or Asperger's syndrome, comprising administering to the oral cavity of a subject in need thereof an effective amount of light.

Provided are a recombinant adenovirus or adenoviral vector expressing GLP1 receptor agonist that shows expected anti-tumor effects and prolonged survival time in tumor-bearing subjects and the pharmaceutical composition comprising the same.